Abstract
This study sought to summarize all available evidence on sex differences in adverse drug reactions (ADRs) to heart failure (HF) medication. Women are more likely to experience ADRs than men, and these reactions may negatively affect women's immediate and long-term health. HF in particular is associated with increased ADR risk because of the high number of comorbidities and older age. However, little is known about ADRs in women with HF who are treated with guideline-recommended drugs. A systematic search of PubMed and EMBASE was performed to collect all available information on ADRs to angiotensin-converting enzyme inhibitors, β-blockers, angiotensin II receptor blockers, mineralocorticoid receptor antagonists, ivabradine, and digoxin in both women and men with HF. The search identified 155 eligible records, of which only 11 (7%) reported ADR data for women and men separately. Sex-stratified reporting of ADRs did not increase over the last decades. Six of the 11 studies did not report sex differences. Three studies reported a higher risk of angiotensin-converting enzyme inhibitor-related ADRs in women, 1 study showed higher digoxin-related mortality risk for women, and 1 study reported a higher risk of mineralocorticoid recepto...Continue Reading
Citations
Sep 1, 2019·Journal of Cardiovascular Translational Research·Floor GroepenhoffHester M den Ruijter
Dec 17, 2019·European Journal of Heart Failure·Felice Lin, Barry Greenberg
Sep 3, 2020·Circulation. Cardiovascular Quality and Outcomes·Sandra Marie Dumanski, Sofia Bano Ahmed
Nov 9, 2019·Nature Medicine·Eva Gerdts, Vera Regitz-Zagrosek
Mar 27, 2020·International Journal of Environmental Research and Public Health·Anyuli Gracia GutiérrezAntonio Gimeno-Miguel
Sep 19, 2020·European Journal of Heart Failure·Nasrien E IbrahimUNKNOWN Prospective Study of Biomarkers, Symptom Improvement and Ventricular Remodeling During Entresto Therapy for Heart Failure (P
Dec 18, 2020·Frontiers in Cardiovascular Medicine·Hester Den Ruijter
Mar 4, 2021·Pharmacological Reviews·Franck Mauvais-JarvisJoshua B Rubin
Mar 24, 2021·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Zahari VinarovPatrick Augustijns
May 8, 2021·Clinical Cardiology·Masatake KobayashiJoão Pedro Ferreira
May 11, 2021·Journal of Cardiac Failure·Markus MeyerLars H Lund
May 25, 2021·Frontiers in Cardiovascular Medicine·Marta FarreroBeatriz Díaz Molina
Jun 15, 2021·Clinical and Translational Science·Brittney H DavisNita A Limdi
Jul 16, 2021·Heart·Sophie Heleen BotsHester M den Ruijter
Jul 29, 2021·Nature Reviews. Endocrinology·Michelle M Mielke, Virginia M Miller
May 17, 2021·Pharmacology & Therapeutics·Juan TamargoEva Delpón
Aug 20, 2021·Heart·Rana Hassan, Sofia B Ahmed
Aug 31, 2021·European Heart Journal·Frank L J VisserenUNKNOWN ESC Scientific Document Group
Sep 25, 2021·European Journal of Preventive Cardiology·Frank L J VisserenUNKNOWN ESC Scientific Document Group
May 8, 2021··Alan John MilliganMinsuk Chang